Acurx Pharmaceuticals, Inc.
ACXPNasdaq
$1.55
↓ -2.5%Jul 17 close · end-of-day
Price
1Y↓ -82.0%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$4.2M
Enterprise Value
$4.2M
P/E
—
P/S
—
P/B
0.6
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$7.5M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-106.9%
ROIC
-86.0%
Debt / Equity
—
Net Cash
—
Return 1Y
-82.7%
Company profile
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme. The company is also developing ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria.
- CEO
- David P. Luci
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 3
- Headquarters
- New York
- Website
- www.acurxpharma.com
Earnings
ACXP Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$0.62↓ -71.2%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | — | — | — | — | -$14.1M | -$8.1M |
| Net income | -$4.6M | -$12.7M | -$12.1M | -$14.6M | -$14.1M | -$8.0M |
| Diluted EPS | -$0.74 | -$1.49 | -$1.12 | -$1.15 | -$17.45 | -$5.32 |
| Operating cash flow | -$3.4M | -$5.0M | -$7.5M | -$9.8M | -$10.4M | -$6.8M |
| Free cash flow | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$4.1M | -$2.8M | — | -$2.2M | -$2.3M | -$2.0M | -$1.6M | -$1.7M |
| Net income | -$4.1M | -$2.8M | -$2.8M | -$2.1M | -$2.2M | -$2.0M | -$1.6M | -$1.7M |
| Diluted EPS | -$5.21 | -$3.45 | -$8.51 | -$2.15 | -$1.89 | -$1.23 | -$0.05 | -$0.62 |
| Operating cash flow | -$2.9M | -$2.2M | -$2.3M | -$2.1M | -$1.7M | -$1.9M | -$1.2M | -$1.4M |
| Free cash flow | — | — | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
No insider transactions in the last 12 months.
No insider transactions on file.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.